Portfolio leadership and R&D productivity are now part of the same conversation

The pharmaceutical industry has spent the last decade moving away from dependence on single blockbuster assets and towards broader, more complex portfolios spanning specialty care, orphan drugs, biologics, cell and gene therapies, and precision medicine. At the same time, R&D productivity continues to face pressure despite major advances in genomics, translational science, and data-driven discovery.

What is becoming increasingly clear across the industry is that this is no longer just a scientific challenge. It is a leadership challenge, too.

As portfolios become more complex and more capital-intensive, the cost of delayed decisions rises with them. Too many important decisions still get slowed down by layers of governance, unclear ownership, and competing priorities. In many organizations, value is lost not because the science failed, but because decisions came too late.

That shift is changing how boards think about leadership.

Portfolio leadership is increasingly seen as a capital-management role rather than an asset-ownership role. Advancing programs is no longer enough. Boards increasingly value leaders who know when to stop one.

The strongest executives are often the ones who can make difficult calls early, redirect investment decisively, and stay objective when programs no longer justify continued backing. They are expected to balance scientific, clinical, and commercial perspectives without allowing decisions to disappear into committee structures or prolonged governance cycles.

This is creating several noticeable shifts in executive hiring:

• Less emphasis on single-asset “success stories”
• Greater interest in leaders with portfolio or investment committee exposure
• Increased scrutiny around decision speed and organizational influence
• Stronger preference for executives who have visibly terminated programs early, rather than defended them for too long
• Greater openness to external hires, where internal cultures historically rewarded perseverance over judgment

Scientific pedigree still matters, but at the executive committee level, it is increasingly treated as a baseline rather than a differentiator.

The differentiator is judgment under pressure.

When assessing leadership talent, boards are asking more direct questions than they were five years ago:

• Can this leader point to a decision where stopping a programme improved broader portfolio returns?
• How do they prevent unresolved issues from being pushed into committees rather than directly resolved?
• When scientific and commercial priorities conflicted, who made the final call — and why?
• Have they shown the confidence to reallocate capital early, rather than defend sunk costs?
• Can they communicate difficult portfolio decisions credibly to boards, investors, and internal teams?

Technology will continue to reshape drug development. But many of the biggest gains in R&D productivity still come down to leadership: clearer priorities, faster decisions, and the confidence to stop pursuing the wrong opportunities early.